Information Hub

Clinical News

2019-03-28

Neratinib shows clinical benefit in HER2-mutant cervical cancer patients

According to the results from the phase 2 SUMMIT basket trial, neratinib demonstrated clinical efficacy in patients with metastatic HER2-mutant cervical cancer.

Source:

2019 SGO Annual Meeting

2019-03-28

Avapritinib demonstrates clinical activity in patients with advanced gastrointestinal stromal tumors with KIT and PDGFRA mutations

According to the results from the phase I NAVIGATOR trial presented at the 2018 CTOS Annual Meeting, avapritinib showed substantial clinical benefit across all lines of therapy for GIST patients.

Source:

2018 CTOS Annual Meeting

2019-03-28

Crizotinib demonstrates clinical activity among patients with inflammatory myofibroblastic tumor (IMFT)

According to a result from a phase 2 study, crizotinib showed positive results in patients with advanced, inoperable inflammatory myofibroblastic tumors.

Source:

2018 CTOS Annual Meeting

2019-03-05

Combination of Dabrafenib and Trametinib Shows Clinical Benefit in Patients with BRAF-Mutant Biliary Tract Cancer

In the phase 2 basket ROAR study, combination of dabrafenib and trametinib demonstrated clinical benefit in patients with BRAF-mutant biliary tract cancer.

Source:

J Clin Oncol 37, 2019

2019-03-05

Trastuzumab, capecitabine, oxaliplatin and pembrolizumab as first-line treatment demonstrates encouraging activity in HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma

Combination of trastuzumab, capecitabine, oxaliplatin and pembrolizumab showed promising results in patients with HER2-positive metastatic esophagogastric cancer.

Source:

J Clin Oncol

2018-12-04

Olaparib significantly improves PFS in BRCA-mutated ovarian cancer as frontline maintenance therapy

In the phase 3 SOLO-1 study, olaparib as frontline maintenance therapy showed significant PFS improvement in ovarian cancer patients carrying BRCA mutation

Source:

N Engl J Med

2018-12-04

Rucaparib shows encouraging anti-tumor activity in metastatic castration-resistant prostate cancer with a deleterious BRCA alteration

According to the preliminary data of TRITON2 study, rucaparib showed anti-tumor activity in metastatic castration-resistant prostate cancer patients carrying BRCA mutation.

Source:

Annals of Oncology

2018-12-04

FDA granted accelerated approval of lorlatinib in ALK+ NSCLC

Based on data from a phase II study (B7461001), the FDA approved lorlatinib for the treatment of patients with ALK positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors (TKIs)

Source:

FDA

2018-12-04

Infigratinib shows meaningful clinical activity in patients with intrahepatic cholangiocarcinoma (IHC) containing FGFR2 fusions

According to updated phase II findings presented at the 2018 ESMO Congress, infigratinib, a selective pan-FGFR kinase inhibitor, demonstrated a clinical meaningful activity in patients with IHC.

Source:

2018 ESMO Congress

2018-12-04

A combination therapy can be used to control the disease of osimertinib-resistant lung cancer patients with RET gene fusion

This study indicated that RET fusion mutation is one of the mechanisms of drug resistance in EGFR-mutant lung cancer patients after osimertinib treatment. A combination therapy provides a new strategy to overcome the drug resistance

Source:

Piotrowska Z, et al., Cancer Discov